Boehringer Ingelheim: all 2,305 studies
Page 9 of 24. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431274Phase 3Results posted
- GLORIA-AF Registry Program (Phase I)CompletedNCT01428765Results posted
- Investigation of Ritonavir Effects on Afatinib Exposure in Healthy SubjectsCompletedNCT01426958Phase 1Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsCompletedNCT01422876Phase 3Results posted
- Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)CompletedNCT01417156Phase 2Results posted
- Phase I Trial of BI 836845 for Various Solid CancerCompletedNCT01403974Phase 1Results posted
- BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)CompletedNCT01403948Phase 1Results posted
- Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedNCT01399619Phase 3Results posted
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)TerminatedNCT01397201Phase 2Results posted
- Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) TherapyTerminatedNCT01397162Phase 2Results posted
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).TerminatedNCT01396278Phase 2Results posted
- Drug Interaction Study With Rifampicin and AfatinibCompletedNCT01396265Phase 1Results posted
- Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal HyperfiltrationCompletedNCT01392560Phase 2Results posted
- ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical PracticeCompletedNCT01388166Results posted
- A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate AsthmaCompletedNCT01383499Phase 2Results posted
- Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin TabletCompletedNCT01383356Phase 1Results posted
- Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
- Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy VolunteersCompletedNCT01371006Phase 1Results posted
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT01370005Phase 3Results posted
- Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01368081Phase 3Results posted
- a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease PatientsCompletedNCT01361009Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
- Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With HypertensionCompletedNCT01353274Results posted
- BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid TumoursCompletedNCT01348347Phase 1Results posted
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male VolunteersTerminatedNCT01348165Phase 1Results posted
- Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian VolunteersCompletedNCT01347086Phase 1Results posted
- A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.CompletedNCT01346540Phase 1Results posted
- LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3Results posted
- LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT01345669Phase 3Results posted
- Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant UseCompletedNCT01344629Phase 1Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedNCT01343888Phase 3Results posted
- Safety Tolerability and Pharmacokinetic of BI 409306CompletedNCT01343706Phase 1Results posted
- Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 DiabetesCompletedNCT01342484Phase 2Results posted
- Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent AsthmaCompletedNCT01340209Phase 3Results posted
- Drug Drug Interaction of BI 201335 and TenofovirCompletedNCT01340196Phase 1Results posted
- Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients IICompletedNCT01335477Phase 3Results posted
- Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis PatientsCompletedNCT01335464Phase 3Results posted
- A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
- Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)TerminatedNCT01329549Phase 1Results posted
- Drug-drug Interaction of Empagliflozin (BI 10773) and MicrogynonCompletedNCT01328184Phase 1Results posted
- Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast CancerCompletedNCT01325428Phase 2Results posted
- Monotherapy Dose Finding With BI 847325 in Solid TumoursCompletedNCT01324830Phase 1Results posted
- Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour TypesCompletedNCT01317420Phase 1Results posted
- Twynsta Study With Lifestyle Modifications in Korean Patients With HypertensionCompletedNCT01316419Results posted
- Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent AsthmaCompletedNCT01316380Phase 3Results posted
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes MellitusCompletedNCT01316341Phase 1Results posted
- BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal CancerCompletedNCT01314105Phase 1Results posted
- A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe AsthmaCompletedNCT01311661Phase 2Results posted
- SMS Reminder to Assess AdherenceCompletedNCT01308476Results posted
- Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusCompletedNCT01306214Phase 3Results posted
- Drug Interaction Study of Digoxin and BI 10773CompletedNCT01306175Phase 1Results posted
- Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy SubjectsCompletedNCT01306162Phase 1Results posted
- Drug-drug Interaction of Empagliflozin (BI 10773) and SimvastatinCompletedNCT01304329Phase 1Results posted
- Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal VolunteersCompletedNCT01303445Phase 1Results posted
- Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy VolunteersCompletedNCT01301742Phase 1Results posted
- Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of AfatinibCompletedNCT01298063Phase 1Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01296932Phase 1Results posted
- Bioequivalence of Two Different Capsule Types of DabigatranCompletedNCT01290757Phase 1Results posted
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesCompletedNCT01289990Phase 3Results posted
- Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)CompletedNCT01286558Phase 3Results posted
- Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy VolunteersCompletedNCT01284621Phase 1Results posted
- Telmisartan and Amlodipine Versus Monocomponent TabletsCompletedNCT01278797Phase 1Results posted
- Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent AsthmaCompletedNCT01277523Phase 3Results posted
- Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-componentsCompletedNCT01276327Phase 1Results posted
- DDI Between BI Empagliflozin (10773) and VerapamilCompletedNCT01276301Phase 1Results posted
- Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesCompletedNCT01276288Phase 1Results posted
- LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment FailuresCompletedNCT01271725Phase 2Results posted
- Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent AsthmaCompletedNCT01257230Phase 3Results posted
- A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus DocetaxelCompletedNCT01251653Results posted
- A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsCompletedNCT01248364Phase 2Results posted
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT01243424Phase 3Results posted
- A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination TherapyCompletedNCT01243268Results posted
- Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female VolunteersCompletedNCT01242176Phase 1Results posted
- Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During HaemodialysisCompletedNCT01241539Phase 1Results posted
- Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.CompletedNCT01233284Phase 2Results posted
- PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to WarfarinCompletedNCT01227629Phase 2Results posted
- BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement SurgeryCompletedNCT01225822Phase 2Results posted
- Tiotropium Respimat Pharmacokinetic Study in COPDCompletedNCT01222533Phase 2Results posted
- Telmisartan 80mg Non-responder TrialCompletedNCT01222520Phase 3Results posted
- Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy VolunteersCompletedNCT01216397Phase 1Results posted
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyCompletedNCT01215097Phase 3Results posted
- BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid TumoursCompletedNCT01214616Phase 1Results posted
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlCompletedNCT01214239Phase 3Results posted
- Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male VolunteersCompletedNCT01214109Phase 1Results posted
- Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on BioavailabilityCompletedNCT01211197Phase 1Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With MetforminCompletedNCT01210001Phase 3Results posted
- An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid TumoursCompletedNCT01206816Phase 1Results posted
- Telmisartan+Amlodipine Fixed Dose Combination in HypertensionCompletedNCT01204398Phase 3Results posted
- Comprehensive Add on Study in JapanCompletedNCT01204294Phase 3Results posted
- Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT01195675Phase 1Results posted
- Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-studyCompletedNCT01194830Phase 3Results posted
- Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01193218Phase 2Results posted
- Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) PatientsCompletedNCT01191944Phase 3Results posted
- Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of FoodCompletedNCT01189201Phase 1Results posted
- Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran EtexilateCompletedNCT01184989Phase 4Results posted
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksCompletedNCT01183013Phase 3Results posted
- Telmisartan, Amlodipine and Combination in Healthy SubjectsCompletedNCT01181011Phase 1Results posted
- Tiotropium Bromide in Cystic FibrosisCompletedNCT01179347Phase 3Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01177813Phase 3Results posted